Patent Cliffs in the Era of Complex Therapies and Biologics

@article{Sabatini2020PatentCI,
  title={Patent Cliffs in the Era of Complex Therapies and Biologics},
  author={M. Sabatini and Miguel Silva},
  journal={Pharmaceutical Medicine},
  year={2020},
  volume={34},
  pages={271 - 278}
}
The rise of new product classes such as biologics and complex molecules over the past two decades have brought to light some of the unique market dynamics that such products face. While we have seen and experienced the inception, growth and expansion phase of such products, the ongoing incumbent decline due to loss of exclusivity (LoE) is yet to be fully experienced. This raises the question of how one may go about modelling such a scenario given that forecasting the expected erosion curves… Expand
View on Springer
ncbi.nlm.nih.gov

Figures and Tables from this paper

References

SHOWING 1-10 OF 43 REFERENCES
The patent cliff steepens
TLDR
The availability of generic atorvastatin will provide health-care payers with another price-discounted option in addition to statins such as simvastasin for managing cholesterol levels in patients, says Gideon Heap, an analyst at Datamonitor Healthcare. Expand
The economics of biosimilars.
TLDR
Various factors, such as safety, pricing, manufacturing, entry barriers, physician acceptance, and marketing, will make the biosimilar market develop different from the generic market. Expand
Patent expiry dates for biologicals : 2017 update
  • 2018
Although small molecule drugs still dominate the global pharmaceutical market in terms of numbers, biologicals are making a significant dent. However, the high cost of biologicals is putting… Expand
May your drug price be evergreen
TLDR
The author analyses all drugs on the market between 2005 and 2015, combing through 60,000 data points to examine every instance in which a company added a new patent or exclusivity, showing a startling departure from the classic conceptualization of intellectual property protection for pharmaceuticals. Expand
The Biosimilar Action Plan: An Effective Mechanism for Balancing Biologic Innovation and Competition in the United States?
The strain between balancing pharmaceutical innovation and competition in the United States (U.S.) is centered around the need to ensure that the U.S. continues to encourage medical innovation while… Expand
May your drug price be evergreen.
Presenting the first comprehensive study of evergreening, this article examines the extent to which evergreening behavior—which can be defined as artificially extending the protection cliff—may… Expand
Are trade secrets delaying biosimilars?
TLDR
It is estimated that even by 2020, biosimilar competition will reduce consumer prices only modestly, and one key reason is the barrier to competitive entry created by trade secrecy in biologics manufacturing. Expand
Patent cliff and strategic switch: exploring strategic design possibilities in the pharmaceutical industry
TLDR
This systematic review explores various strategic and tactical management approaches by synthesizing the relevant literature and practical examples on patent expiration strategies and offers both theoretical and practical guidelines for strategy transformation that companies can use to prolong the market exclusivity. Expand
Did the Demand for Crestor Shrink when Lipitor’s Patent Expired?
This paper uses micro-level data from the Medical Expenditure Panel Survey to investigate whether, following the expiration of Lipitor’s patent, demand for Crestor shrank. The topic holds important… Expand
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
TLDR
Differences in approach in phase 3 testing must be viewed in the totality of evidence demonstrating biosimilarity, with differences in clinical trial design (equivalence or non-inferiority design), patient population, patient population and endpoint (overall response rate or pathological complete response). Expand
...
1
2
3
4
5
...